$20.50
1.63[8.64%]
At close: Apr 26
$20.50
0[0.00%]
After Hours: 6:01PM EDT
AnaptysBio
(NASDAQ:ANAB)Latest News for AnaptysBio Stock (NASDAQ:ANAB)
AnaptysBio Stock (NASDAQ: ANAB)
Categories: All
Tuesday, April 16, 2024
Thursday, April 11, 2024
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 11, 2024, 1:33PM
- Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Apr 11, 2024, 10:01AM
- Wells Fargo Initiates Coverage On AnaptysBio with Overweight Rating, Announces Price Target of $56Benzinga Newsdesk - Apr 11, 2024, 9:45AM
Monday, April 01, 2024
Tuesday, March 12, 2024
- Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical TriggersVandana Singh - Mar 12, 2024, 2:48PM
- AnaptysBio shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform.Benzinga Newsdesk - Mar 12, 2024, 12:19PM
- Wedbush Upgrades AnaptysBio to OutperformBenzinga Newsdesk - Mar 12, 2024, 7:11AM
Monday, March 11, 2024
Monday, February 26, 2024
Wednesday, February 21, 2024
Friday, January 05, 2024
Wednesday, November 29, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
Wednesday, November 01, 2023
Wednesday, October 11, 2023
Monday, October 09, 2023
- Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?Vandana Singh - Oct 9, 2023, 9:26AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Oct 9, 2023, 9:06AM
- Market-Moving News for October 9thBenzinga Newsdesk - Oct 9, 2023, 8:54AM
- AnaptysBio shares are trading higher after the company announced imsidolimab met the primary endpoint of its global Phase 3 GEMINI-1 trial, achieving rapid clearance of GPP through Week 4 after a single dose.Benzinga Newsdesk - Oct 9, 2023, 8:40AM
- AnaptysBio Shares Resume TradeBenzinga Newsdesk - Oct 9, 2023, 8:35AM
- Anaptys To Provide Overview Of Rosnilimab, A PD-1 Agonist, At Virtual R&D Event On Wednesday, Oct. 25Benzinga Newsdesk - Oct 9, 2023, 8:19AM
- AnaptysBio, Inc. Shares To Resume Trade At 8:30 a.m. ETBenzinga Newsdesk - Oct 9, 2023, 8:03AM
- Anaptys Announces Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular PsoriasisBenzinga Newsdesk - Oct 9, 2023, 8:01AM
- AnaptsysBio Trading Halt: Halt News PendingCharles Gross - Oct 9, 2023, 7:59AM
Tuesday, September 19, 2023
Monday, September 18, 2023
Tuesday, August 08, 2023
Monday, July 31, 2023
- Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's SessionLisa Levin - Jul 31, 2023, 3:30PM
- AnaptysBio- And GSK-Partnered Immuno-Oncology Agent JEMPERLI Plus Chemotherapy Approved In The U.S. For dMMR/MSI-H Primary Advanced Or Recurrent Endometrial CancerHappy Mohamed - Jul 31, 2023, 1:37PM
Monday, July 24, 2023
Friday, July 21, 2023
Monday, May 22, 2023
Friday, May 12, 2023
Thursday, May 11, 2023
Tuesday, May 02, 2023
Wednesday, April 12, 2023
Tuesday, March 28, 2023
- GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer PatientsVandana Singh - Mar 28, 2023, 12:04PM
- Reported Late Monday March 27, AnaptysBio And GSK Partnered Immuno-Oncology Agent Jemperli Plus Chemotherapy Demonstrates Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival For The Treatment Of Primary Advanced Or Recurrent Endometrial Cancer Versus Chemotherapy Alone In Phase 3 Ruby TrialHappy Mohamed - Mar 28, 2023, 12:59AM
Wednesday, March 01, 2023
Friday, January 13, 2023
Friday, January 06, 2023
- Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Jan 6, 2023, 1:16PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Jan 6, 2023, 12:30PM
- Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On FridayLisa Levin - Jan 6, 2023, 11:17AM
- Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023Benzinga Insights - Jan 6, 2023, 10:00AM